Status:
COMPLETED
Effects of Latanoprost on Choroidal Blood Flow Regulation in Human Subjects
Lead Sponsor:
Medical University of Vienna
Conditions:
Ocular Physiology
Intraocular Pressure
Eligibility:
MALE
19-35 years
Phase:
NA
Brief Summary
Latanoprost is a synthetic prodrug of 17-phenyl-substituted prostaglandin F2α analog. Used at a dose of one drop per day, it has been reported to produce a 30 to 35% reduction in intraocular pressure....
Eligibility Criteria
Inclusion
- Men aged between 19 and 35 years, nonsmokers
- Body mass index between 15th and 85th percentile (Must et al. 1991)
- Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
- Normal ophthalmic findings, ametropia \< 3 dpt.
Exclusion
- Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study
- Treatment in the previous 3 weeks with any drug
- Symptoms of a clinically relevant illness in the 3 weeks before the first study day
- History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with distribution, metabolism or excretion of study drugs
- Blood donation during the previous 3 weeks
- Ametropia \>= 3 dpt
- Iris bicolor
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00712400
Start Date
June 1 2005
End Date
January 1 2010
Last Update
June 11 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Clinical Pharmacology
Vienna, Austria, 1090